Unusual case of long survival patient with leptomeningeal carcinomatosis from breast cancer

2021 ◽  
pp. 1-4
Author(s):  
Giovanni Pennisi ◽  
Benedetta Burattini ◽  
Marco Gessi ◽  
Nicola Montano ◽  
Alessia Perna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Unusual Case ◽  
Leptomeningeal Carcinomatosis ◽  
Long Survival

Isolated Leptomeningeal Carcinomatosis (Carcinomatous Meningitis) after Taxane-Induced Major Remission in Patients with Advanced Breast Cancer

Oncology ◽  
2002 ◽  
Vol 63 (1) ◽  
pp. 6-15 ◽  
Author(s):  
Christos Kosmas ◽  
Nikolaos A. Malamos ◽  
Nikolas B. Tsavaris ◽  
Melina Stamataki ◽  
Achilleas Gregoriou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Leptomeningeal Carcinomatosis ◽  
Advanced Breast ◽  
Carcinomatous Meningitis

scholarly journals Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review

CNS Oncology ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. CNS65
Author(s):  
Leonor Fernandes ◽  
Leonor Vasconcelos de Matos ◽  
Débora Cardoso ◽  
Marlene Saraiva ◽  
Renata Medeiros-Mirra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Leptomeningeal Carcinomatosis ◽  
Luminal Breast Cancer ◽  
Leptomeningeal Disease ◽  
Targeted Agents ◽  
Published Evidence ◽  
Cns Activity ◽  
Evidenced Based

Leptomeningeal disease (LMD) represents a devastating complication of advanced breast cancer (ABC), with survival of <5 months with multimodal treatment. The role of endocrine therapy (ET), due to its favorable toxicity profile and first-line indication in luminal ABC, appears promising in the setting of LMD, where symptom stabilization and quality-of-life preservation are the main goals; however, evidenced-based data are lacking. We conducted a thorough review of published evidence, aiming to investigate the role of ET in LMD treatment in luminal ABC. Twenty-one of 342 articles, evaluating 1302 patients, met inclusion criteria. ET use was rarely reported. New targeted agents show CNS activity. Research is lacking on the role of ET and targeted agents in BC-LMD treatment.

LEPTOMENINGEAL CARCINOMATOSIS IN PATIENTS WITH BREAST CANCER: PATHOLOGICAL, CLINICAL PARAMETERS AND OUTCOME. A SINGLE INSTITUTION’S EXPERIENCE

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. S75-S76
Author(s):  
Nektarios Alevizopoulos ◽  
Konstantinos Folinas ◽  
Theodoros Tegos ◽  
Areti Dimitriadou ◽  
Michail Pavlakis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Leptomeningeal Carcinomatosis ◽  
Clinical Parameters

An Unusual Case of Scalp Metastasis from Breast Cancer

2020 ◽  
Vol 137 ◽  
pp. 261-265
Author(s):  
Yu-fei Liu ◽  
Ling-yu Liu ◽  
Shi-lin Xia ◽  
Tao Li ◽  
Jun Li
Keyword(s):  
Breast Cancer ◽  
Unusual Case ◽  
Scalp Metastasis

Long survival in advanced breast cancer

JAMA ◽  
1983 ◽  
Vol 249 (12) ◽  
pp. 1538-1539
Author(s):  
M. L. Fuerst
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Long Survival

scholarly journals 56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS

2020 ◽  
Vol 2 (Supplement_2) ◽  
pp. ii11-ii12
Author(s):  
Wulin Jiang ◽  
Alain Valdivia ◽  
Alison Mercer-Smith ◽  
Carey Anders ◽  
Shawn Hingtgen
Keyword(s):  
Breast Cancer ◽  
Spinal Cord ◽  
Cancer Cells ◽  
Limit Of Detection ◽  
Human Fibroblasts ◽  
Leptomeningeal Carcinomatosis ◽  
Leptomeningeal Disease ◽  
Breast Cancer Patients ◽  
Tumor Homing ◽  
The Brain

Abstract INTRODUCTION Leptomeningeal carcinomatosis remains one of the most lethal forms of central nervous system metastasis, with a median survival of only 4 months. Effective new therapies are urgently needed to treat this highly aggressive cancer. In this study, we used models of both prophylactic and established leptomeningeal disease to investigate the efficacy of engineered tumor-homing neural stem cells (NSCs) therapy for breast cancer leptomeningeal carcinomatosis. METHODS Personalized NSC carriers were created using Sox2 overexpression to transdifferentiate human fibroblasts into induced NSCs (iNSCs) that home to cancer cells and carry therapeutic agents to induce tumor kill. Leptomeningeal models were created by engineering MDA-MB231-Br human breast cancer cells with fluorescent and bioluminescent reporters, then using intracisternal injection to inoculate Nude mice with the tumor cells. iNSC therapy was evaluated by infusing iNSCs releasing the pro-apoptotic agent TRAIL into the lateral ventricle of mice either 1 week prior to or 3 days after tumor inoculation for prophylactic or established tumor treatment respectively. Tumor progression in the brain and spinal cord was monitored by serial bioluminescence imaging (BLI). RESULTS Serial BLI showed that intracerebroventricular (ICV) iNSC-TRAIL therapy reduced the volume of metastatic tumor burden 99.49% in the brain and 99.80% in the spine within 2 weeks post-infusion and extended survival from 24 to 42 days. Additionally, prophylactic iNSC-TRAIL therapy delivered ICV markedly delayed tumor development, with tumors in the brain remaining &gt;1000-fold smaller than control through 1-month post-treatment, below the limit of detection in the spinal cord through 1 month, and eliminating mortality through 50 days post-therapy. CONCLUSION These data suggest that iNSC therapy could be a promising treatment option for breast cancer patients with leptomeningeal carcinomatosis.

Sign in / Sign up

Export Citation Format

Share Document